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Abstract: Dysregulation of transcriptional pathways is observed in multiple forms of neurodevelop-
mental disorders (NDDs), such as intellectual disability (ID), epilepsy and autism spectrum disorder
(ASD). We previously demonstrated that the NDD genes encoding lysine-specific demethylase 5C
(KDM5C) and its transcriptional regulators Aristaless related-homeobox (ARX), PHD Finger Protein
8 (PHF8) and Zinc Finger Protein 711 (ZNF711) are functionally connected. Here, we show their
relation to each other with respect to the expression levels in human and mouse datasets and in vivo
mouse analysis indicating that the coexpression of these syntenic X-chromosomal genes is temporally
regulated in brain areas and cellular sub-types. In co-immunoprecipitation assays, we found that the
homeotic transcription factor ARX interacts with the histone demethylase PHF8, indicating that this
transcriptional axis is highly intersected. Furthermore, the functional impact of pathogenic mutations
of ARX, KDM5C, PHF8 and ZNF711 was tested in lymphoblastoid cell lines (LCLs) derived from
children with varying levels of syndromic ID establishing the direct correlation between defects in
the KDM5C-H3K4me3 pathway and ID severity. These findings reveal novel insights into epigenetic
processes underpinning NDD pathogenesis and provide new avenues for assessing developmental
timing and critical windows for potential treatments.
Keywords: neurodevelopmental disorders; X-chromosome; KDM5C; H3K4me3; disease mutations;
NDD-related chromatinopathies
1. Introduction
Brain development and neuronal differentiation are complex processes involving
spatio-temporal changes in chromatin remodeling and transcriptional activity in specific
brain regions and neural cell types [1–3]. Alterations in regulatory genes of chromatin re-
modeling and transcription factors (TFs) cause a huge spectrum of neurodevelopmental dis-
orders (NDDs) [2,4–6]. We recently uncovered genetic and functional relationships within
a set of X-linked NDD genes formed by the epigenetic eraser Lysine-Specific Demethylase
5C (KDM5C; MIM:314690) and its upstream regulators, Aristaless-related homeobox (ARX;
MIM:300382), PHD Finger protein 8 (PHF8; MIM:300560) and Zinc Finger protein 711
(ZNF711; MIM:314990) [4,5]. KDM5C encodes a highly conserved JmjC-domain protein
that reverts the H3K4me3 substrate into di- and mono-methylated products, acting as a
fine-tuning transcriptional regulator essential for dendritic spine plasticity [7–9]. Mutations
in KDM5C were generally found in male children with X-linked syndromic Intellectual
Disability (XLID) Claes-Jensen type (MIM:300534), characterized by moderate to severe
ID, spasticity, epileptic seizures, short stature, and microcephaly [10–12] or showing a
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developmental delay with or without ASD-like signs [13]. Point mutations or defective
gene expression of KDM5C may compromise its demethylase activity leading to target
gene expression deregulation [5,14]. ARX encodes a homeotic bi-functional TF capable of
activating or repressing gene transcription [15]. Mutations in ARX have been found in a
wide range of NDDs, affecting only male children and including severe cortical malforma-
tions such as X-linked Lissencephaly with agenesis of the corpus callosum and ambiguous
genitalia (XLAG; MIM:300215); Agenesis of Corpus Callosum (ACC; MIM 300004; also
known as Proud syndrome); severe pediatric epilepsy such as Developmental and Epileptic
Encephalopathy 1 (DEE1; MIM:308350, also known as West syndrome); and mild cognition
diseases including Partington syndrome (MIM 309510), autism, and non-syndromic intel-
lectual disability [4,16–20]. Previous studies conducted by us and other groups have shown
that XLAG mutations abrogate the transcriptional program controlled by ARX, whereas
expansions of the polyA-tracts are hypomorphic mutations with reduced transcriptional
activity and binding properties [4,5,15,21,22]. PHF8 encodes a histone demethylase whose
mutations were found in male children patients with Siderius X-linked mental retardation
syndrome (MRXSSD; MIM:300263) characterized by ID, microcephaly, and cleft lip and
palate [23–25]. Finally, ZNF711 encodes a TF of the Krüppel C2H2-type zinc-finger protein
family that binds mainly to GC-rich CpG island promoters [26]. Variants in ZNF711 have
been found in children with non-syndromic ID (MIM:300803) presenting mild to mod-
erate cognition defect and poor speech accompanied by autistic features and mild facial
dysmorphisms in some patients [27–29]. Of interest, both KDM5C and its transcriptional
regulatory genes are dispersed across the X-chromosome that has been historically targeted
for ID studies because variants in these genes give rise to familial recurrence of cognitive
defects that affect males more often and more severely than females [30]. Although we
have some knowledge of the intersecting regulation of this set of NDD genes, little is
currently known about their transcriptional trajectories in the developing brain [5,31].
Consequently, there is no information on their relation to each other with respect to the
expression profiles in specific brain areas and/or neuronal cells. To fill this gap, we here
report on where and when KDM5C and its three regulatory genes are coexpressed. To this
end, we integrated data available in public human and mouse databases with in vivo
studies performed on embryonic and neonatal mouse brains. Additionally, in NDD patient-
derived lymphoblastoid cell lines (LCLs) mutated in KDM5C and in its regulatory genes,
we also figure out the functional correlation between gene mutation severity and the defect
in the KDM5C-H3K4m3 pathway.
2. Materials and Methods
2.1. Animals
Protocols for animals were approved by the Italian Ministry of Health (DLgs116/92)
in accordance with the Institutional Animal Care guidelines of the Institute of Genetics and
Biophysics Adriano Buzzati-Traverso.
2.2. Identification of Cap Analysis of Gene Expression (CAGE) Derived Transcription Start Sites
Cap Analysis of Gene Expression (CAGE) is a powerful experimental technique
for assisting in the identification of transcription start sites (TSSs;) [32,33]. The FANTOM
Consortium2 has extensively applied CAGE on hundreds of tissues and cell lines of humans
and mice and characterized the regulatory mechanisms of gene expression. Analysis of
FANTOM5 database was performed using Zenbu browser genomic data visualization tools
(https://fantom.gsc.riken.jp/zenbu/ accessed on 1 May 2021). Robust CAGEs defined
by DPI clustering falling inside the RefSeq regions of KDM5C, ARX, PHF8 and ZNF711
genes were selected. The expression values are shown in Tags Per Million (TPM) calculated
on a per-library total expression. TPM values were obtained for each CAGE using the
FANTOM5 expression dataset for tissues, cell lines, and primary cells in human and mouse
(Supplementary Tables S1 and S2).
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2.3. Cell Lines, Transient Transfection, and Luciferase Assay
SH-SY5Y cell line was maintained in Dulbecco’s modified Eagle’s medium (Life
Technologies™ Scotland, Swindon, UK) supplemented with 10% fetal bovine serum (FBS,
Life Technologies™ Bleiswijk, Bleiswijk, The Netherlands), 100 units/mL penicillin and
100 mg/mL streptomycin (Gibco BRL, Paisley, Scotland). For lymphoblastoid cell line (LCL)
establishment, peripheral blood mononuclear cells (PBMCs) were isolated and cultured in
RPMI 1640 (Life Technologies, Swindon, UK) using standard methods. All cell lines were
tested regularly for mycoplasma contamination.
Transient transfections were performed according to standard methods [4]. The re-
porter activities were measured using the Dual-Luciferase Reporter Assay System (Promega
Corporation Madison, Madison, WI, USA). Each assay was performed in duplicate in three
independent experiments and the resulting firefly luciferase values were normalized using
the renilla values.
2.4. Plasmids
The wild-type ARX expression plasmid and its mutants c.298_330dup33 [p.Ala105
_Ala115] and c.429_452dup24 [p.Ala148_Ala155] have been previously described [4]. The
pCMV-HA tagged PHF8, pCMV-Myc tagged PHF8, and pCMV-Myc tagged ZNF711 con-
structs expressing the human cDNA of PHF8 and ZNF711 are a gift from K. Helin (Center
for Epigenetics Research at Memorial Sloan Kettering Cancer Center & University of
Copenhagen, København, Denmark) described elsewhere [34]. Immunoblot analysis of the
transfected cell lysates was performed to prove that the overexpressed protein levels were
present in all cell lines.
2.5. Western Blotting and Protein Interaction Assays
Protein extracts from mammalian cells and tissues were prepared and separated
following standard methods [5]. After the blocking of nonspecific binding sites on the
membranes with 5% non-fat milk, the membranes were incubated with specific antibodies.
The following antibodies were used: anti-ARX (2 µg/mL final; H70 sc-98895, Santa Cruz
Biotechnology, Inc. Europe, Heidelberg, Germany), anti-KDM5C (1:1000, H-99 sc-98701,
Santa Cruz Biotechnology, Inc. Europe, Heidelberg, Germany), anti-H3K4me3 (1:5000, AB-
8580, Abcam Cambridge, Waltham, MA, USA), anti-PHF8 (1:500, Millipore 09-868, Merck,
Darmstadt, Germany), anti-SYN1 (1:300, Calbiochem 574777, Merck, Darmstadt, Germany),
anti-ZNF711 (1:1000, AB-187324, Abcam Cambridge, Waltham, MA, USA). Anti-β-actin
(1:3000, C4 sc-47778, Santa Cruz Biotechnology, Inc. Europe, Heidelberg, Germany) was
used as loading controls. The signals were detected with an enhanced chemiluminescence
kit (Amersham Biosciences, British Isles, Buckinghamshire, UK) and the films were pro-
cessed for densitometric scanning. The protein interaction studies were performed using
Dynabeads® Protein G Immunoprecipitation Kit (Thermo Fisher Scientific, Waltham, MA,
USA) following the manufacturer’s instructions. For the immunoprecipitation assays of the
endogenous PHF8 and ARX, total lysates from SH-SY5Y cells were used. After SDS-page,
Western blotting was performed using anti-ARX (1:500, H70 sc-98895, Santa Cruz Biotech-
nology, Inc. Europe, Heidelberg, Germany) and anti-PHF8 (1:500, Millipore 09-868, Merck,
Darmstadt, Germany) antibodies. For the co-immunoprecipitation assays, the SH-SY5Y
cells were transfected with the expression vectors pCMV-HA-PHF8, pCMV-Myc-ZNF711
and pCMV-Myc-ARX. The antibodies used were the anti-cMyc antibody (1:5000, Clone
9E10 M4439, Sigma, Saint Louis, MO, USA) and anti-HA antibody (1:5000, AB-9110, Abcam
Cambridge, Waltham, MA, USA). The flow-through derived from each experiment was
tested as a negative control of the binding specificity.
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2.6. RNA Extraction and Real-Time Polymerase Chain Reaction
Total RNA extraction was carried out with TRIzol procedure (Life Technologies,
Scotland, Swindo, UK). Reverse transcription was performed with a QuantiTect Reverse
Transcription kit (Qiagen, Hilden, Germany) and steady-state mRNA abundance was
determined using the Power SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) on the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). Sequences of oligonucleotide primers used in qRT-PCR are reported in
Supplementary Table S3. Each experimental assay was performed in triplicate in three
independent experiments.
2.7. Statistical Analysis
The statistical analyses were performed with the GraphPad Prism 4 software (Graph-
Pad Software) to calculate the significance of the differences among each sample against
the control. One-way ANOVA test with Bonferroni correction or the Student’s t-test was
used. The standard error of the mean was used to estimate variation within a single assay.
3. Results
3.1. Spatiotemporal Expression Patterns of KDM5C and Its Regulatory Genes in Human and
Mouse Brain
To test whether KDM5C and its three regulator genes are coexpressed across embry-
onic and adult brain tissues, we used public resources of the Human Brain Transcriptome
Atlas available at https://hbatlas.org/hbtd/basicSearch.pl (accessed on 2 April 2021) [35].
In six brain areas—neocortex (NCX), hippocampal formation (HIP), amygdala (AMY),
striatum (STR), midbrain (MB), and cerebellum (CBC)—we observed the high expression
levels of the two erasers KDM5C and PHF8 in the early days of neuronal development
(period 1: embryonic development 4 < Age < 8 PCW corresponding to the first lamination
of the cerebral wall; Figure 1A,B). Then, we observed a progressively declined decrease
with age until the birth (period 7: late fetal development 24 < Age < 38 PCW characterized
by the transition from the typical fetal lamination pattern into an adult-like lamination
pattern of the cerebral wall; Figure 1A,B). The transcription factor genes ARX and ZNF711
showed a progressive increase in the early stages of development until period 3 (early fetal
development 10 < Age < 13 PCW characterized by the presence of the bilaminate cortical
plate) and period 4 (early mid-fetal development 13 < Age < 16 PCW characterized by the
consolidation of the cortical plate and the formation of a large, synapse-rich subplate zone).
In particular, ARX showed an oscillator expression profile exhibiting an increase in STR
(period 3; Figure 1A,B), followed by a change in the opposite direction, with a progressive
decreasing trend in the remaining five brain areas, from the early days of neuronal develop-
ment to the birth (Figure 1A,B). Regarding ZNF711, its gene expression increased gradually
from the first days of neuronal development with a peak at the middle of the embryonic
phase and then gradually decreased until birth (period 3; Figure 1A,B). Additional evi-
dence for their coexpression during neuronal differentiation derives from transcriptomics
resources of human induced pluripotent stem cells (hiPSC) differentiated into neurons
(Supplementary Figure S1; http://stemcell.libd.org/scb/ accessed on 1 August 2021). Fur-
thermore, in the postnatal lifespan, we observed a similar trend for each NDD gene among
the regional expression profiles in human brain (Figure 1A). In addition, we analyzed the
expression profile of the X-linked epilepsy gene Synapsin I (SYN1; MIM:313440; [36]), a
repressed downstream target of KDM5C encoding a neuronal phosphoprotein involved in
synaptic neurotransmission [5]. In agreement with this regulation pattern, we observed a
gradual increase of SYN1 in each of the six brain areas, from the early days of conception
to the birth (Figure 1A).




Figure 1. Expression profiles of KDM5C, ARX, PHF8, and ZNF711 during development and in the adult human brain.
(A) Data from Human Brain Transcriptome Atlas are shown in RPKM. Original images can be accessed freely at https:
//hbatlas.org/hbtd/basicSearch.pl (accessed on 2 April 2021). Period 1, 4 < Age < 8 postconceptional weeks (PCW); Period
2, 8 < Age < 10 PCW; Period 3, 10 < Age < 13 PCW; Period 4, 13 < Age < 16 PCW; Period 5, 16 < Age < 19 PCW; Period
6, 19 < Age < 24 PCW; Period 7, 24 < Age < 38 PCW; Period 8, Neonatal and early infancy, birth ≤ Age < 6 postnatal
months; Period 9, Late infancy, 6 < Age < 12 postnatal months; Period 10, Early childhood, 1 < Age < 6 years; Period 11,
Middle and late childhood, 6 < Age < 12 years; Period 12, Adolescence, 12 < Age < 20 years; Period 13, Young adulthood,
20 < Age < 40 years; Period 14, Middle adulthood, 40 < Age < 60 years; Period 15, Late adulthood, 60 + years [35]. Embryonic
development (E), from 1 to 7; birth and infancy (I), from 8 to 9; childhood (C), from 10 to 11; adolescence (Ac), 12; adulthood
(Ad), from 13 to 15. Brain regions: neocortex (NCX), hippocampal formation (HIP), amygdala (AMY), striatum (STR),
midbrain (MB), cerebellum (CBC). (B) A glimpse of developmental-stage-specific chronology for neurogenesis (from the
embryonic life to the adult stage in human).
Next, we assessed the dynamics of this regulatory axis during mouse embryonic
development (at E12.5, E14.5, and E18.5) and during post-natal life (at birth, P0, and
P10; Figure 2A–C). By real-time PCR and western blot analysis, we observed that Kdm5c
(GenBank NM_145997.2), Arx (GenBank: BC052033.1), Znf711 (in mouse named Zfp711,
GenBank: NM_177747.3), and Phf8 (GenBank: BC138899.1) are all highly expressed at the
beginning of neurogenesis (between E12.5 and E14.5), both at mRNA and protein levels
(Figure 2A–C). Then, the level of Kdm5c/KDM5C gradually decreases during synapse
formation (from E18.5 to P10; Figure 2A–C), as well as Zfp711/ZFP711 and Phf8/PHF8.
Regarding the level of Arx/ARX, we observed a gradual decrease from E18.5 to P10 as
mRNA and a similar protein band from E12.5 to P0 that declines after birth (Figure 2A,B).
Taken together, these data provide evidence that the expression patterns of Kdm5c and
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its regulatory genes overlap prenatally and disappear post-natally. Moreover, in situ
hybridization images obtained from the Allen Institute for Brain Science showed that in
adult male mice, Kdm5c, Arx, Phf8, and Zfp711 are coexpressed mainly in the hippocampus
and olfactory bulbs (Supplementary Figure S2; https://mouse.brain-map.org/ accessed
on 8 April 2021). Noteworthily, the hippocampus and olfactory bulbs are the sites of adult
neurogenesis [37]. We also tested the level of Syn1, which transcriptional expression is
known to be repressed by KDM5C [38,39]. As expected, the SYN1 protein displays a
later onset (E18.5) followed by a gradual increase after birth, which inversely mirrors the
decrease of KDM5C (Figure 2B). In conclusion, these findings highlight that in both human
and mouse, the KDM5C/Kdm5c transcriptional regulation is organized into coexpression




Figure 2. Expression profiles of Kdm5c, Arx, Phf8 and Zfp711 in embryonic and neonatal mouse brain. Representative
quantitative real-time PCR (A) and western blot analysis (B) of Arx/ARX, Phf8/PHF8, Kdm5c/KDM5C, Syn1/SYN1 and
Zfp711/ZFP711, throughout prenatal and postnatal stages in the whole WT murine brain. The transcript analysis was
performed in triplicate and the samples were normalized to 18S. The bars indicate the mean ± standard error of three
independent experiments. The Western blotting experiment was repeated three times. The beta-actin antibody (β-actin)
was used as a loading control. (C) Schematic representation of the neuronal developmental time line (days) from conception
to birth and from birth until 30 days after birth (P30).
3.2. CAGE-Defined TSSs of KDM5C and Its Regulatory Genes in Human and Mouse Brain
We analyzed data of promoter level expression across the transcriptome of different
brain areas and neuronal cells from the FANTOM 5 project database [40] (https://fantom.
gsc.riken.jp/zenbu/ accessed on 1 May 2021). By using the Cap Analysis of Gene Expression
method (CAGE), we identified the predominantly used transcription start sites (TSSs) for
the four genes KDM5C, ARX, PHF8, and ZNF711 (Supplementary Figure S3 and Table S1).
Specifically, we established that in human brain, the highest used TSS for KDM5C is
p1@KDM5C located at chrX:53211978-53263129(-); for ARX, it is p1@ARX located at chrX:
25034067-25034088(-); for PHF8, we identified p1@PHF8, located at chrX:54070731-54070781(-),
and p2@PHF8 located at chrX:54070879-54070917(-); and for ZNF711, it is p1@ZNF711 lo-
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cated at chrX:84498989-84499003(+) (Supplementary Figure S3A–C and Table S1). In mouse
brain, the highest used Kdm5c TSS is p1@Kdm5c located at chrX:148667771-148667803(+);
for Arx, it is p1@Arx located at chrX:90531838-90531861(+); for Phf8, it is p1@Phf8, located at
chrX:147955689-147955749(+), and p2@Phf8 located at chrX:147955198-147955224(+); and for
Zfp711, it is p1@Zfp711 located at chrX:109714331-109714347(+) (Supplementary Figure S3A–
C and Table S1). Successively, we extracted the expression value for each TSS measured as
tag per million (TPM) (Figure 3A–C). We generated the heatmap of human promoters using
the value of TPM expression (Figure 3A; Supplementary Table S2). We found a strong expres-
sion of p1@KDM5C, p1@ARX, p1@PHF8, p2@PHF8 and p1@ZNF711 (expression module
embryonic-e) in fetal sub-areas of the cortex (Figure 3A, panel e). In line with these evidences,
the TSSs of the four NDD genes are expressed in a fetal brain pool (59 samples between
20-33 weeks; CNhs1086459—from p1@ARX, the most expressed, to p1@PHF8, the least ex-
pressed (Figure 3B; Supplementary Table S2). Moving to neonatal and adult brain samples,
we found several changes with respect to fetal profiles (Figure 3A, panels n and a). In the
neonatal brain samples, the coexpression of the TSSs is still present but less strong (expres-
sion module neonatal-n). Instead, in the adult samples, we observed a robust coexpression
only of p1@KDM5C and p2@PHF8 since the levels of p1@ARX and p1@ZNF711 are severely
reduced in most of the adult samples (expression module adult-a; Figure 3A, panel a). More
interestingly, primary neuronal cells showed a weak coexpression of p1@KDM5C, p1@ARX,
p2@PHF8, and p1@ZNF711 (expression module-neuron cell-c; Figure 3A), while astro-
cytes showed two distinctive coexpression profiles: p1@KDM5C, p1@PHF8, and p2@PHF8
in cerebellum (expression module-astrocyte cerebellum-c; Figure 3A); and p1@KDM5C,
p1@ARX, p1@PHF8, p2@PHF8, and p1@ZNF711 (expression module-astrocyte cortex-c;
Figure 3A). Additionally, in neuronally differentiated induced pluripotent stem cells (iPS),
we observed that p1@KDM5C, p1@ARX, p2@PHF8, and p1@ZNF711 are expressed from
the induction of neuro-ectodermal cells (day 6) to the generation of early neuronal progeni-
tors (day 18). They showed an oscillatory trend with a peak of p1@ARX and p2@PHF8 at
day6 and of p1@KDM5C and p1@ZNF711 at day 12 corresponding to the generation of
self-renewing multipotent neural stem cells (Figure 3C).
In neonatal mice, we found a strong expression of p1@Kdm5c, p1@Arx, p2@Phf8, and
p1@Zfp711 in corpus striatum (STR) and hippocampus (HIP), both at age N10 (expression
module STR/HIP-n) and in visual cortex at age N15 (Figure 3D and Supplementary Table S2).
In adult mice, we noted a strong expression of all TSSs only in the olfactory area (expression
module OP-a). In the remaining areas, a strong decrease in p1@Arx was observed in cortex
(CX), HIP, and cerebellum (CB) with respect to OP (expression module CX/HIP/CB-a;
Figure 3D). Moving to primary cells, we found strong expression of all TSSs in neurons
isolated from HIP and STR (coexpression module HIP/STR-c; Figure 3D). Of note, p1@Arx
is poorly expressed in neurons of the substantia nigra but strongly expressed in astrocytes
of the CB and HIP. Moreover, in CB, the coexpression of p1@Kdm5c and p1@Zfp711 is
evident, and the weak expression of p1@Phf8, p2@Phf8, while p1@Arx expression was not
detected (Figure 3E; Supplementary Table S2). Collectively, the TSS data obtained both in
human and mouse samples strongly support the hypothesis that KDM5C/Kdm5c, ARX/Arx,
ZNF711/Zfp711, and PHF8/Phf8 constitute a core regulatory network activated consistently
in the same or distinctive cell type or brain areas in mammals.




Figure 3. Expression profiles of TSSs in human (A–C) and mouse (D,E) brain samples. Heat map showing the TPM
expression of all promoters in sub-regions of brains and brain-related primary cells in human (A). Expression profiles of
p1@KDM5C, p1@ARX, p1@PHF8, p2@PHF8, and p1@ZNF711 in human fetal brain (B) and in human iPS differentiated to
neuron (C), (day 6 = neuro-ectodermal cells; day 12 = neural stem cells; day 18 = early neuronal progenitors). The expression
of each CAGE promoter is reported as TPM on the y-axis. Heatmap showing the TPM expression of all promoters in
sub-regions of brains and brain-related primary cells in mice (D). Expression profiles of p1@Kdm5c, p1@Arx, p1@Phf8,
p2@Phf8, and p1@Zfp711 in mouse cerebellum (E). Heatmap’s data are normalized and are reported as percentages with
respect to the largest value in each data set. Data are available at https://fantom.gsc.riken.jp (accessed on 1 May 2021).
3.3. KDM5C, ARX, PHF8, and ZNF711 Are Syntenic Genes of Human/Mouse X-Chromosome
Gene order is not random with regard to gene expression in mammals but is main-
tained by natural selection because it has a functional significance [41]. We analyzed
genome annotations of KDM5C and its regulatory genes on human (UCSC Genome
GRCh37/hg19) and mouse (UCSC Genome GRCm38/mm10) genome assembly. As shown
in Figure 4, the four genes KDM5C, ARX, PHF8, and ZNF711 are all located in syntenic
blocks of X chromosome. Specifically, the nearby genes KDM5C (hg19 chrX: 53,220,503–
53,254,604) and PHF8 (hg19 chrX: 53,963,113–54,071,569), at physical distance between them
of 708 Kb—map to the region of human X chromosome p11.22. This region is syntenic to the
inverted region of the mouse X chromosome qF3 where their murine counterparts, Kdm5c
(mm10 chrX: 152,233,229–152,274,535) and Phf8 (mm10 chrX: 151,520,672–151,625,833),
map—physical distance between them is 607 Kbs. The human ARX (hg19 chrX: 25,021,
811-25,034,082) maps to the Xp21.3 region syntenic to the inverted region of mouse X chro-
mosome qC3 where maps the murine Arx orthologue (mm10 chrX: 93,286,496–93,298,357)
maps; and finally, the human ZNF711 (hg19 chrX: 84,498,997–84,528,368) maps to the Xq21.1
region syntenic to the mouse X chromosome qE1, where the murine counterpart named
Zfp711 maps (mm10 chrX: 112,600,526–112,635,062). Although it lacks an understanding of
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how these clusters may exist in mammals and what their functional significance is, we may
assume that—due to their functional relationship during the brain development—KDM5C




Figure 4. KDM5C, ARX, PHF8, and ZNF711 are located in syntenic segments of human and mouse X chromosome (ChrX_
human and ChrX_mouse, respectively). SynBrowser map of the human and mouse X chromosome and the regions
containing the genes (not to scale; http://bioinfo.konkuk.ac.kr/synteny_portal/, accessed on 1 May 2021). Block linkages
in the same orientation are labelled in pink (ChrX human Xq21.1 vs. ChrX mouse XqE1), while those in inverted orientation
are labelled in green (ChrX human Xp21.3 vs. ChrX mouse XqC3) or in violet (ChrX human Xp11.22 vs. ChrX mouse XqF3).
Nucleotide positions of each block are shown.
3.4. ARX Interacts with PHF8
In a previous study, we showed that PHF8 and ARX acted cooperatively to in-
duce KDM5C stimulation [5]. Therefore, we wondered whether this activity is medi-
ated by a molecular interaction of PHF8 with ARX. To this end, we evaluated by co-
immunoprecipitation (Co-IP) the ability of these regulatory transcriptional factors to in-
teract directly in both endogenous and transiently transfected conditions. As shown in
Figure 5A, endogenous ARX was immunoprecipitated by the anti-PHF8 antibody and vice
versa, suggesting a direct protein-protein interaction. In addition, the formation of the
ARX/PHF8 complex was observed in the coexpression of the HA- and Myc-tagged versions
of PHF8 and ARX (Figure 5B). The coexpression of the HA- and Myc-tagged version of
PHF8 and ZNF711 was tested as the positive control of their direct interaction, as previously
described [34] (Figure 5B). Thus, our results have revealed a direct connection between
PHF8 and ARX, expanding the regulatory intersection of KDM5C stimulation (Figure 5C).




Figure 5. Co-immunoprecipitation of PHF8 and ARX in SH-SY5Y cells. Co-IP of endogenous PHF8 and ARX and vice versa.
Cell lysates were subjected to immunoprecipitation with anti-PHF8 or anti-ARX antibodies. The presence of PHF8 and
ARX in the cell extracts prior to immunoprecipitation was checked using anti-PHF8 and anti-ARX antibodies (Input) (A).
Cells were transfected with a pCMV vector to express HA tagged-PHF8 (120 kDa), or Myc tagged-ARX (75 kDa), or Myc
tagged-ZNF711 (100 kDa) (B). The cell lysates were subjected to immunoprecipitation with anti-HA or anti-Myc- antibodies.
The presence of PHF8-HA, ZNF711-Myc, and ARX-Myc in cell extracts prior to immunoprecipitation was checked using
anti-HA and anti-Myc antibodies (Input). Regulatory interactions with activating effects on KDM5C transcription are shown
in the carton (C).
3.5. Analysis of KDM5C and H3K4me3 Levels in NDD Patient-Derived Lymphoblastoid
Cell Lines
We set out to investigate on KDM5C expression and H3K4me3 levels in Epstein-Barr
virus (EBV)-transformed lymphoblastoid cell lines (LCLs) obtained from eight NDD pa-
tients (P) with mutations in KDM5C or in its three regulators (Table 1). Specifically, the
NDD P1 and P2 LCL cells were obtained from two unrelated male patients, presenting
mild cognition defects, who carry the same in-frame ARX duplication c.429_452dup24
[p.A148_A155dup] (Figure 6A; [4,18,42,43]). From P3 to P6, LCLs were obtained from four
male patients with mutations in KDM5C characterized by a variable degree of ID and
comorbidities. Specifically, the nonsense mutations c.3864G>A [p.W1288X] [10,44] and
c.1599delC [p.W534Gfs*15] [45] from patients P3 and P4, respectively, are both character-
ized by severe ID with epilepsy (Table 1); the missense mutation c.1162G>C [p.A388P] [10]
in patient P5, presents ID with mild facial dysmorphism (Table 1); and the missense muta-
tion c.2248C>T [p.R750W] [46] in patient P6, presents severe ID and speech impairment
(Table 1). P7 LCLs were obtained by a male patient with ID and cleft/lip palate who carries
the nonsense mutation c.1050_1061del12 [p.P314fs*] in PHF8 [23] (Table 1). Finally, P8
LCLs were obtained from a male patient with mild ID who carries the missense mutation
c.731T>C [p.I244T] in ZNF711 [29] (Table 1).
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Table 1. List of disease mutations analyzed in this study.
Gene cDNA Change Protein Change Mutation Clinical Features Reference
ARX c.298_330dup33 p.Ala105_115dup duplication DEE1, severe ID [4,18,42,43]
c.429_452dup24 p.Ala148_155dup duplication mild ID [4,18,42,43]
KDM5C c.1162G>C p.Ala388Pro missense ID, mild dysmorphism [10]
c.3864G>A p.Trp1288X nonsense severe ID, spasticity, epilepsy,microcephaly [10,44]
c.1599delC p.Trp534Glyfs*15 nonsense severe ID, epilepsy, spasticity [45]
c.2248C>T p.Arg750Trp missense severe ID, speech impairment [46]
PHF8 c.1050_1061del12 p.Pro314fs* nonsense mild to borderline ID, cleft lip andcleft palate [23]
ZNF711 c.731T>C p.Ile244Thr missense mild to borderline ID, speech delay [29]
ID, Intellectual disability; DEE1, Developmental epileptic encephalopathy-type 1.
By real-time PCR, we firstly detected a variable expression of the KDM5C mRNA in
patient-derived LCLs with respect to the control male-derived LCLs (Figure 6A): in the
ARX, P1 and P2 patients expressed 57% and 56% lower compared with the WT controls,
respectively; in KDM5C, P3-P6 expressed 41%, 47%, 60%, and 29%, respectively; in PHF8,
P7 expressed 31%; and in ZNF711, P8 expressed 5%. Secondly, by Western blotting we
tested the protein levels of KDM5C and of its main substrate trimethylation of lysine 4 of
histone H3 (H3K4me3). In line with the real-time-PCR data, we found that all mutations in
ARX, PHF8, and ZNF711 lead to a decrease in KDM5C protein content (Figure 6B). This
defect inversely correlates with an increase in the H3K4me3 level, potentially as the result
of the compromised demethylase activity of KDM5C (Figure 6B). These findings suggest
that the mutations in KDM5C regulators act on the KDM5C-H3K4m3 pathway as partial
loss-of-function because of a variable basal activity depending on the type of mutations.
About KDM5C mutations, the nonsense KDM5C p.W1288X and KDM5C p.W534Gfs*15
mutations operate as loss-of-function mutations since they are incapable of synthesizing
the relative proteins, and thus, of demethylase H3K4me3 (Figure 6B). Noteworthily, the
missense mutation KDM5C p.A388P, showed a protein intensity band of KDM5C and
H3K4me3 similar to that of the WT. In line with the predicted impact on the protein
conformation reported previously [47], we conclude that this missense mutation does not
impair the demethylase activity but instead alters the binding to other proteins, perhaps
involved into the recruitment of KDM5C to specific target promoters.
On the contrary, for the missense mutation p.R750W, the respective KDM5C protein
band was severely reduced and the H3K4me3 band increased, with respect to the control.
For this alteration, one explanation is that the substitution of the evolutionarily conserved
arginine with a tryptophan residue in C5HC2-Zinc Finger domain of KDM5C [46] might
cause a reduced protein stability followed by a protein degradation process operating as
partial loss-of-function. We conclude that in NDD patient-derived cell lines, as a result
of the KDM5C decrease (partial LoF) or the KDM5C absence (LoF), the global levels of
H3K4me3 signal increase determine a perturbation of chromatin remodeling.




Figure 6. KDM5C defects associated to NDD mutations. KDM5C expression in lymphoblastoid cell lines obtained from
distinct NDD patients mutated in ARX, KDM5C, PHF8, and ZNF711. The percentages indicate the expression variation
with respect to the WT, which has a mean of seven (n = 7) different cell lines from male age-matched males. The transcript
analysis was performed in triplicate and the samples were normalized to 18S. The bars indicate the mean ± standard error
of three independent experiments (top panel). Positions of the studied mutations are shown in the cartoon (bottom panel). OP,
Octapeptide; polyA, polyalanine tracts; NLS, Nuclear localization sequences; HD, homeodomain; OAR, Aristaless domain;
JmN, jumonji-N domain; ARID, AT-rich interacting domain; PHD, plant homeodomain box domain; JmjC, jumonji-C
catalytic domain; ZF, zinc finger domain; PLU-1, PLU-1-like domain; Zfx/Zfy, Transcription activation domain (A). Western
blotting for KDM5C and its substrate H3K4me3 was performed on cellular extracts from LCLs. The β-actin antibody
(β-actin) was used as a loading control. Each experiment was repeated with two independent LCL protein extracts with
similar results (B). Effects of PHF8 and ZNF711 overexpression on KDM5C 5′ UTR region in cotransfection with ARX
polyalanine elongated mutants. Each luciferase assay was performed in duplicate in four independent experiments. The
bars indicate the mean ± standard error of four independent experiments (C). * p < 0.05; ** p < 0.005; **** p < 0.0005; ns,
not significant.
3.6. The Defective ARX-Dependent Transactivation of KDM5C Is Balanced by PHF8 or
ZNF711 Overexpression
We previously showed that the loss of promoter stimulation of KDM5C caused by
PHF8 mutant proteins was rescued by ZNF711 coexpression; while the loss of KDM5C activ-
ity of mutant ZNF711 proteins was not compensated by WT PHF8 coexpression [5]. Expand-
ing this analysis, we cotransfected the JD-full-Luc construct with full-length Myc-tagged
ARX (GenBank: NM_139058.2) WT and p.Ala105_Ala115dup and p.Ala148_Ala155dup
mutant expressing vectors into SH-SY5Y cells (Figure 6C; Table 1). We observed that
the coexpression of ZNF711 with PHF8 or individually led to normalization of the in-
terfering defects of ARX-KDM5C interaction, associated with p.Ala105_Ala115dup and
p.Ala148_Ala155dup mutations, increasing the luciferase quantity score back to the level
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obtained with the ARX WT construct (Figure 6C). This suggests that both the overexpres-
sion of ZNF711 and PHF8 might balance the impairment of the stimulation of KDM5C
promoter in case of ARX mutations with partial loss-of-function.
4. Discussion
Spatiotemporal gene expression differences across specific brain regions are guided
by regulatory interactions through epigenetic modifications and transcriptional changes.
Here, we reveal that a set of NDD genes, encoding the demethylases KDM5C and PHF8
and the transcription factors ARX and PHF8, is highly interconnected, showing a strongly
coordinated expression pattern across neurogenesis and during neuronal differentiation
of hiPSCs. These genes show a peculiar coexpression pattern in hippocampal and neo-
cortical regions, with two intersected cardinal areas involved in flexible cognition and
social behavior [48]. Moreover, three of them—KDM5C, ARX, and PHF8—show high
expression levels at the timing of neuronal proliferation with a decrease during neuronal
migration and synaptogenesis—two highly vulnerable processes underpinning neural
circuit development [2]. By contrast, ZNF711 shows an oscillatory trend with a very low
expression level during the proliferation phase that increases, reaching a peak at the begin-
ning of neuronal migration and synaptogenesis (Figure 7A). In embryonic and neonatal
mouse brain, transcript and protein levels of Kdm5c, Arx, Phf8, and Zfp711 show a similar
framework: all four genes, and their relative proteins, are mainly coexpressed during the





Figure 7. Heatmaps showing the expression profiles of KDM5C/Kdm5c and its regulatory genes ARX/Arx, PHF8/Phf8,
and ZNF711/Zfp711. Data were obtained from Allen Brain Atlas/Transcriptomics Explorer in human (A) and mouse (B).
Original images can be accessed freely at https://celltypes.brain-map.org/rnaseq/ (accessed on 10 July 2021).
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Additional data based on FANTOM5 CAGE database reinforce the concept that this
set of NDDs shows overlapping time-specific transcriptional modules. They operate
during brain development—where they are involved in neuronal cell specification—and in
adult brain areas—where they control neuronal plasticity and functioning. Noteworthily,
CAGE analysis was successfully applied to characterize regulatory intersection among
genes found mutated in other NDDs—such as Rett Syndrome—and build the atlas of
TSS across major human cell-types and tissues [32,49]. The entry into the scene of the
three regulating genes at various times of neurogenesis suggests that transcription of
the epigenetic eraser KDM5C has a multi-level regulatory governance—particularly in
human—capable of ensuring the correct dosage of KDM5C in response to specific stimuli
at the proper time and in the proper tissue area or cell. Moreover, further investigation on
the roles of these transcriptional modules in specific cell subtypes, such as glutamatergic
neurons, GABAergic neurons and glia cells should be performed. To this end, single-cell
RNA sequencing studies allow defining single cell coexpression landscapes and identifying
targeted cells for potential treatments [50]. Remarkably, as reported in the Human Protein
Atlas dataset (https://www.proteinatlas.org/ accessed on 10 July 2021), KDM5C and its
three regulatory proteins ARX, ZNF711 and PHF8 are all expressed in the corpus callosum,
in human, pig, and mouse (Table S4). Deciphering whether these subsets of NDD genes are
mutually related to the development of callosal projection neurons (CPN), will shed light
on the molecular mechanisms controlling the formation of the corpus callosum, a structure
that connect the two cortical hemispheres. Noteworthily, one of the allelic disorders caused
by ARX mutations is Proud syndrome, presenting as a main clinical features the agenesis
of the corpus callosum [51]. Nevertheless, no gross alterations in the corpus callosum have
been reported in patients mutated in KDM5C, ZNF711, and PHF8 [10,23,29,44–46].
Since defects in GABAergic neurons feature prominently in NDDs, another interesting
aspect that requires deep investigation is that whether this subset of NDD genes is mutually
involved in differentiation and functioning of GABAergic interneurons. By interrogating
the Allen Brain Atlas RNAseq database, it is evident that they are mutually coexpressed
in specific subsets of GABAergic neurons, both in human and mouse (Figure 7A,B; [52]).
The direct involvement of ARX and KDM5C in GABAergic-related activities has been
already reported [4,5,9,53]; while it is unknown the role of ZNF711 and PHF8 is unknown.
Furthermore, 3D human organoids from patients could help to identify in detail the
functional impact of each of them on the production of GABAergic neurons and whether
they could alter the balance between GABAergic and glutamatergic neurons.
Another interesting observation is that the localization of KDM5C and its regulatory
genes is conserved within synthenic blocks of X chromosomes in human and mouse. This
conserved localization parallels their coexpression profiles in human and mouse nervous
system, suggesting that the coordinated waves of gene expression during neurogenesis and
in specific brain areas is controlled by conserved regulatory mechanisms. Indeed, binding
sites for key lineage and/or tissue-specific transcription factors could be simultaneously
recruited at the enhancers and active promoters of this set of X-linked genes. On the other
hand, clustering of genes expressed during the early phases of brain development could
be advantageous to assemble chromatin neighbourhoods with open conformation. More-
over, further studies are required to define whether they fall into the same topologically
associating domain (TAD) and/or share common regulatory players.
Chromatin perturbations associated to mutations in neurodevelopmental genes dam-
age vulnerable brain processes such as cognition development and neuronal homeosta-
sis [2,3]. Notably, in patient-derived LCLs with mutations in KDM5C, ARX, PHF8, and
ZNF711, we detected aberrant dosage of KDM5C and H3K4me3.
This suggests that the neurological diseases linked to this set of genes can be con-
sidered as X-linked chromatinopathies. Specifically, the aberrant levels of KDM5C and
H3K4me3 in ID males mutated in KDM5C, ZNF711, PHF8, and ARX highlight a variable
chromatin defect as a consequences of the type of disease mutation. This secondary disease
hit could cause a relaxation in the chromatin conformation and compromise nervous system
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development. In reference to this, we observed a direct relationship between the severity
of the KDM5C-H3K4me3 defect with the severity of cognition impairment. This feature
highlights the value of KDM5C as a disease epigenetic marker to predict ID severity caused
by mutations in its gene (direct effect) or in its regulator genes (indirect effect) (Figure 8B).
Obviously, the KDM5C-H3K4m3 axis is not the solely damaged process, but other path-
ways can be altered as a result of mutations in genes involved in pleiotropic activities, such
as ARX, ZNF711, or PHF8. We therefore propose a model explaining that the varying sever-
ity of ID, a common clinical core associated to the four disease genes, could be explained
through the impact on KDM5C-H3K4me3 axis (Figure 8B). On the other hand, the identi-
fication of further regulatory elements of the KDM5C transcriptional axis (e.g., cofactors,
interactors, non-coding RNAs, etc.) and molecular compounds capable of modulating
its expression levels (e.g., epidrugs, small peptides, etc.) will contribute to deeply define
how to counteract a KDM5C deficit in time-regulated windows of cognition development.
In this direction are the recent findings on the functional interactions of KDM5C with
lysine methyltransferase 2A (KMT2A; MIM 159555), responsible for Wiedemann-Steiner
Syndrome (WDSTS; MIM:605130), proving that this eraser-writer pair acts in a mutually
suppressive mode, ameliorating their associated disorders [9]. More interestingly, we
have shown that in vitro and in vivo treatments with suberanilohydroxamic acid (SAHA)





Figure 8. KDM5C is an epigenetic marker of ID severity. Regulatory governance of KDM5C transcription (A, left panel); and
expression profiles of KDM5C and its regulatory genes during human neurogenesis (A, right panel); functional correlation
between mutation severity and ID (B).
A peculiar aspect of this highly connected regulatory axis is the capacity to rebalance
the partial loss activity of expanded polyalanine tracts in ARX via overexpression of
the coregulatory proteins ZNF711 or PHF8. Along the same line, we previously found
that ZNF711 overexpression is also capable of balancing the partial loss activity of PHF8
mutant proteins [5]. Collectively, these findings suggest that PHF8 and ZNF711 may act
as gene modifiers of ARX-disease phenotypes; thus, variants in these NDD genes may
contribute to the phenotype variability from West syndrome to Partington syndrome to
mild ID caused by ARX polyalanine expansions. Even though more studies are needed to
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fully understand the peculiar activities of this intersected NDD pathway, we propose that
the KDM5C transcription has a multi-level regulatory governance coupled to a positive
feedback mechanism. In addition, because the expression profiles of KDM5C regulatory
genes are mutually related to multiple cellular subtypes, as callosal projection neuron and
interneurons, they could be involved in differentiation and functioning of varying neuronal
cell types.
5. Conclusions
Our findings indicate that KDM5C is an epigenetic marker of developmental sig-
natures through which we may estimate the functional impact of disease mutations on
cognition processes and that it represents a convergent point for therapeutic intervention
for a set of X-linked chromatinopathies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12071088/s1, Figure S1: Gene expression levels of KDM5C and its regulatory genes
throughout neuronal differentiation. Figure S2: Expression analysis of Kdm5c, Arx, Phf8 and Zfp711
in adult male mouse brain (P56). Figure S3: Zenbu genome browser views of gene locus for
human KDM5C, ARX, PHF8, and ZNF711. Table S1: CAGE annotation from Zenbu database.
Table S2: Human and murine expression data of CAGE obtained from Zenbu database. Table
S3: Oligonucleotides used for transcript analysis. Table S4: RNA expression summary of KDM5C
and its regulatory genes in the corpus callosum (from The Human Protein Atlas datasets; https:
//www.proteinatlas.org/, accessed on 1 May 2021).
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